Purple Biotech Ltd (PPBT) Return on Assets ROA from the fourth quarter of 2024 to fourth quarter of 2022 and for the year 2024, Average High and Low, Fundamental Ratios from Dec 31 2024 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Purple Biotech Ltd  (NASDAQ: PPBT)


Purple Biotech Ltd's ROA from the fourth quarter of 2024 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Purple Biotech Ltd's ROA in the fourth quarter of 2024?
Purple Biotech Ltd achieved a return on average assets (ROA) of 18.6 % in its fourth quarter of 2024, this is above PPBT's average return on assets of -15.12%.
Purple Biotech Ltd assets over the 12 months ending in its fourth quarter of 2024 are valued at $39 million

ROA fell compared to the third quarter of 2024, despite the net income growth of % from the third quarter of 2024.

However, within the Healthcare sector 973 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2024 from to 4195.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2024)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Total Assets Change -52.56 % 51.98 % -50.52 % -21.98 % -21.98 %
Y / Y Net Income Change -66.55 % - - - 17.83 %
Net Income (TTM) in million 7 22 22 22 22
Return On Assets (TTM) 18.6 % 49.45 % 56.59 % 45.42 % 43.08 %
PPBT's Total Ranking # 4195 # # # # 4918
Total Assets (TTM) in million 18 65 37 37 37
Seq. Total Assets Change -72.92 % 75.19 % 0 % 0 % -13.25 %
Seq. Net Income Change - - - - -

PPBT's 5 Years Annual ROA >> Back to PPBT Management Effectiveness >> Compare PPBT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 472
Sector # 974
Overall # 5317

Return On Assets Statistics
High Average Low
37.83 %
-15.12 %
-150.76 %
(Dec 31 2018)   (Dec 31 2025)





Financial Statements
Purple Biotech Ltd's Assets $ 18 million PPBT's Balance sheet
Purple Biotech Ltd's Income $ 7 million Quarterly PPBT's Income Statement
PPBT's Income by Division See PPBT's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -75.02 % 51.98 % -42.96 % -32.08 % 9.74 %
Total Assets in million 16 65 43 75 110
Y / Y Net Income Change - - - - -34.22 %
Net Income in million -26 -7 -20 -22 18
Annual Return On Assets -163.47 % -11.22 % -46.79 % -29.07 % 16.76 %

PPBT's 5 Years Annual ROA >> Back to PPBT Management Effectiveness >> Compare PPBT ROA to its Competitors



More Return On Assets Ratios
PPBT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PPBT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PPBT's Competitors
Subscribers only: Roa for Purple Biotech Ltd's Suppliers
Subscribers only: Return On Assets for PPBT's Customers

You may also want to know
PPBT's Roi PPBT's Inventory Turnover Ratio PPBT's Growth Rates PPBT's Dividend Comparisons
PPBT's Profitability Ratios PPBT's Asset Turnover Ratio PPBT's Dividend Growth
PPBT's Roe PPBT's Valuation Ratios PPBT's Financial Strength Ratios PPBT's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2024, within Healthcare Sector ROA
Gridai Technologies Corp  51.03 %
Adma Biologics Inc   49.22 %
Protagonist Therapeutics inc   42.46 %
Exelixis Inc   41.90 %
Galmed Pharmaceuticals Ltd   40.54 %
Semnur Pharmaceuticals Inc   36.42 %
Edwards Lifesciences Corporation  36.37 %
Dariohealth Corp   35.04 %
Semler Scientific inc   32.68 %
Pharmacyte Biotech Inc   29.33 %
Biomx Inc  27.98 %
Siga Technologies Inc  27.05 %
Idexx Laboratories Inc  26.48 %
Mettler toledo International Inc   26.37 %
Champions Oncology Inc   25.10 %
Entrada Therapeutics Inc   24.31 %
Engene Therapeutics Inc   23.75 %
Inmode Ltd   23.07 %
Acadia Pharmaceuticals Inc   23.03 %
Promis Neurosciences inc   22.98 %
Hims and Hers Health Inc   22.52 %
Halozyme Therapeutics Inc   22.23 %
Catalyst Pharmaceuticals Inc   22.02 %
Novo Nordisk A  21.68 %
Cytomx Therapeutics Inc   21.13 %
Iradimed Corporation  20.76 %
Medpace Holdings Inc   20.47 %
Carlisle Companies Incorporated  20.44 %
Curevac N v   20.20 %
Nrc Health  19.66 %

Date modified: 2026-09-02T18:44:22+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.